Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyViva Health Short-Acting G-CSF Coverage & Prior Au…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0235

    Short-Acting Granulocyte Colony Stimulating Factors (SA-G-CSF)

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0235 alerts

    Get alerted when Policy IC-0235 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, indications, and renewal criteria for short-acting G-CSF products (e.g., Filkri, Granix, Neupogen, Nivestym, Nypozi, Releuko, Zarxio) for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyShort-Acting Granulocyte Colony Stimulating Factors (SA-G-CSF)
    Policy CodePolicy IC-0235
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial validity 120 days) and document prior use or contraindication/intolerance/failure to Nivestym and Zarxio when requesting alternative short-acting G-CSF.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    120 daysinitial PA validity
    120 daysrenewal PA validity
    1560max units/day (severe CN)
    1200max units/day (BMT/PBPC/H-ARS)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    600
    max units/day (other)
    7HCPCS codes listed

    Coverage Criteria for Short-Acting G-CSF

    Covered Indications

    Covered when ALL of the following are met for each indication group as specified:

    Indications eligible for coverage: Member has one of the listed indications: Bone Marrow Transplant (BMT) or Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant; Prophylactic use with solid tumors or non-myeloid malignancy meeting febrile neutropenia risk criteria; Treatment of chemotherapy-induced febrile neutropenia with qualifying risk factors; Neutropenic complication from a prior cycle of the same chemotherapy; Acute Myeloid Leukemia (induction/consolidation or relapsed/refractory disease); BMT failure or engraftment delay; Severe chronic neutropenia (see specific criteria); Myelodysplastic Syndromes meeting specified criteria; Acute exposure to myelosuppressive radiation (H-ARS); CAR T-cell–related neutropenia; Wilms tumor with favorable histology used with a cyclophosphamide-based regimen (Regimen M or I only); Pediatric aggressive mature B-cell lymphomas.

    Prophylactic use criteria

    Prophylactic use in members with solid tumors or non-myeloid malignancy is covered when:

    Prophylaxis criteria: Member is undergoing myelosuppressive chemotherapy with an expected incidence of febrile neutropenia >20%; OR expected incidence 10%–20% AND one or more member-related risk factors; OR expected incidence <10% AND two or more member-related risk factors. Use in the <10% setting is based on clinical judgment. Note: dose-dense therapy generally requires growth factor support; in palliative settings consider dose reduction or regimen change.

    Treatment of febrile neutropenia

    Treatment of chemotherapy-induced febrile neutropenia is covered when ALL of the following:

    Treatment criteria: Member has febrile neutropenia (temperature and neutropenia per policy definition) AND either has been receiving prophylactic short-acting G-CSF (note: do not use concomitantly with a long-acting G-CSF) OR has not received prophylactic G-CSF; AND member has one or more of the following risk factors for infection-related complications: sepsis syndrome; age >65 years; ANC <100/mcL; expected duration of neutropenia >10 days; pneumonia or other clinically documented infections; invasive fungal infection; hospitalization at the time of fever; or prior episode of febrile neutropenia.

    Severe chronic neutropenia

    Severe chronic neutropenia is covered when ALL of the following are met:

    Severe chronic neutropenia criteria: Absolute neutrophil count (ANC) < 500/mm3; AND diagnosis of one of the following: congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

    Myelodysplastic Syndromes (MDS)

    Myelodysplastic Syndromes coverage requires ALL of the following:

    MDS criteria: Member has symptomatic anemia without del(5q); AND lower-risk disease (IPSS-R Very Low, Low, or Intermediate); AND serum erythropoietin ≤ 500 mUnits/mL; AND used in combination with an erythropoiesis-stimulating agent (ESA); AND either: ring sideroblasts ≥15% (or ≥5% with SF3B1 mutation) and used following no response to or relapse after luspatercept; OR ring sideroblasts <15% (or <5% with SF3B1) and used following no response to (despite adequate iron stores) or relapse after ESAs alone, OR following no response to or relapse after luspatercept. (No response defined by hemoglobin or transfusion criteria per policy.)

    Used in combination with a cyclophosphamide-based chemotherapy regimen (Regimen M or I only)

    Wilms tumor with favorable histology is covered when ALL of the following are met for the specified regimens:

    Wilms tumor (Regimen M or I only): Member has Wilms tumor (nephroblastoma) with favorable histology; AND therapy is used in combination with a cyclophosphamide-based chemotherapy regimen (Regimen M or Regimen I only).

    Renewal Criteria

    Renewal criteria — prior authorization may be renewed when ALL of the following are met:

    Renewal criteria: Member continues to meet the indication-specific relevant criteria identified in the initial approval section (including any concomitant therapy requirements and performance status); AND there is absence of unacceptable toxicity from the drug (examples include splenic rupture, ARDS, serious allergic reactions/anaphylaxis, sickle cell crisis, glomerulonephritis, leukocytosis, capillary leak syndrome, aortitis, alveolar hemorrhage/hemoptysis, thrombocytopenia, cutaneous vasculitis, MDS/AML when applicable, etc.).

    Do not administer a short-acting G-CSF at the same time as a long-acting G-CSF. The policy explicitly states that therapy with a short-acting granulocyte colony-stimulating factor should not be used concomitantly with a long-acting G-CSF when treating chemotherapy-induced febrile neutropenia or related indications.

    No exclusion criteria are specified in the provided excerpts. The related sections contain only NDC listings for short-acting G-CSF products (examples include Zarxio, Releuko, Neupogen, and Nivestym) and should be used for product identification and billing.

    These chunks do not contain explicit coverage decision statements or exclusion conditions. They provide NDCs and product identifiers for short-acting G-CSF products to support pharmacy billing and product identification.

    No explicit exclusions or clinical coverage limitations are stated in these excerpts; the content is limited to product NDC lists and references for filgrastim products and biosimilars used for claims and dispensing.

    Medicare rules may supersede plan-level guidance for beneficiaries covered under Part B. National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) — and any applicable Local Coverage Articles — must be followed where relevant. The preceding information in this policy is intended for non‑Medicare coverage determinations and additional CMS guidance may apply.

    No statements declaring items as not medically necessary appear in the provided excerpts. The referenced sections list NDCs and product presentations without 'not medically necessary' determinations.

    Within the supplied excerpt there are no explicit 'not medically necessary' determinations. The text is limited to listing product presentations and their NDCs for identification and billing.

    For Wilms tumor with favorable histology, the policy specifies use of short-acting G-CSF only when it is used in combination with a cyclophosphamide-based chemotherapy regimen (Regimen M or I only) as listed in the covered regimens.

    Coding and Billing Codes

    Billing/HCPCS units and availabilityHCPCS
    HCPCS UnitUnits and maximums described per product/indication (see dosing limits)
    HCPCS CodesHCPCS
    J1442Injection, filgrastim (g-csf), excludes biosimilars, 1 mcg: 1 billable unit = 1 mcg
    Q5110Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg: 1 billable unit = 1 mcg
    Q5101Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg: 1 billable unit = 1 mcg
    J1447Injection, tbo-filgrastim (Granix), 1 mcg: 1 billable unit = 1 mcg
    Q5125Injection, filgrastim-ayow, biosimilar, (Releuko), 1 mcg; 1 billable unit = 1 mcg
    Q5148Injection, filgrastim-txid (nypozi), biosimilar, 1 microgram; 1 billable unit = 1 mcg
    J3590Unclassified biologics (Filkri Only)
    C9399Unclassified drugs or biologicals (Hospital Outpatient Use Only) (Filkri Only)
    NDCs (selected list shown in document)NDC
    55513-0530-xxNeupogen 300 mcg single-dose vial
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect)
    55513-0546-xxNeupogen 480 mcg single-dose vial
    61314-0246-xxZarxio 300 mcg single-dose vial
    61314-0318-xxZarxio 300 mcg single-dose prefilled syringe
    61314-0266-xxZarxio 480 mcg single-dose vial
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe
    00069-0293-xxNivestym 300 mcg single-dose vial
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe
    00069-0294-xxNivestym 480 mcg single-dose vial
    1–10 of 12
    1/2
    Listed NDCs for SA-GCSF productsNDC
    61314-0318-xxZarxio 300 mcg single-dose prefilled syringe (NDC pattern)
    61314-0266-xxZarxio 480 mcg single-dose vial (NDC pattern)
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe (NDC pattern)
    70121-1569-xxReleuko 300 mcg single-dose vial (NDC pattern)
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe (NDC pattern)
    55513-0530-xxNeupogen 300 mcg single-dose vial (NDC pattern)
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect) (NDC pattern)
    55513-0546-xxNeupogen 480 mcg single-dose vial (NDC pattern)
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe (NDC pattern)
    00069-0294-xxNivestym 480 mcg single-dose vial (NDC pattern)
    1–10 of 12
    1/2
    NDCs listed in excerptNDC
    61314-0266-xxZarxio 480 mcg single-dose prefilled syringe (listed)
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe (listed)
    70121-1569-xxReleuko 300 mcg single-dose vial
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe
    55513-0530-xxNeupogen 300 mcg single-dose vial
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect)
    55513-0546-xxNeupogen 480 mcg single-dose vial
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe
    00069-0294-xxNivestym 480 mcg single-dose vial
    00069-0292-xxNivestym 480 mcg single-dose prefilled syringe
    1–10 of 12
    1/2
    NDCs for SA-GCSF productsNDC
    00069-0294-xxNivestym 480 mcg single-dose vial
    00069-0292-xxNivestym 480 mcg single-dose prefilled syringe
    61314-0246-xxZarxio 300 mcg single-dose vial
    61314-0318-xxZarxio 300 mcg single-dose prefilled syringe
    61314-0266-xxZarxio 480 mcg single-dose vial
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe
    70121-1569-xxReleuko 300 mcg single-dose vial
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe
    70121-1571-xxReleuko 480 mcg single-dose vial
    55513-0530-xxNeupogen 300 mcg single-dose vial
    1–10 of 13
    1/2
    NDCs for SA G-CSF products (single-dose vial and prefilled syringe)NDC
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe
    70121-1569-xxReleuko 300 mcg single-dose vial
    70121-1571-xxReleuko 480 mcg single-dose vial
    55513-0530-xxNeupogen 300 mcg single-dose vial
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect)
    55513-0546-xxNeupogen 480 mcg single-dose vial
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe
    00069-0292-xxNivestym 480 mcg single-dose prefilled syringe
    00069-0294-xxNivestym 480 mcg single-dose vial
    61314-0246-xxZarxio 300 mcg single-dose vial
    1–10 of 13
    1/2
    NDCs for short-acting G-CSF productsNDC
    70121-1569-xxReleuko 300 mcg single-dose vial (NDC pattern)
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe (NDC pattern)
    70121-1571-xxReleuko 480 mcg single-dose vial (NDC pattern)
    55513-0530-xxNeupogen 300 mcg single-dose vial (NDC pattern)
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect) (NDC pattern)
    55513-0546-xxNeupogen 480 mcg single-dose vial (NDC pattern)
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe (NDC pattern)
    00069-0294-xxNivestym 480 mcg single-dose vial (NDC pattern)
    00069-0292-xxNivestym 480 mcg single-dose prefilled syringe (NDC pattern)
    61314-0246-xxZarxio 300 mcg single-dose vial (NDC pattern)
    1–10 of 13
    1/2
    NDCs for short-acting G-CSFsNDC
    61314-0266-xxZarxio 480 mcg single-dose prefilled syringe (NDC pattern)
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe (duplicate listing)
    70121-1569-xxReleuko 300 mcg single-dose vial
    70121-1568-xxReleuko 300 mcg single-dose prefilled syringe
    70121-1571-xxReleuko 480 mcg single-dose vial
    55513-0530-xxNeupogen 300 mcg single-dose vial
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect)
    55513-0546-xxNeupogen 480 mcg single-dose vial
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe
    00069-0294-xxNivestym 480 mcg single-dose vial
    1–10 of 13
    1/2
    Listed NDCs for filgrastim productsNDC
    55513-0924-xxNeupogen 300 mcg single-dose prefilled syringe (SingleJect) / appears for 300 mcg
    55513-0530-xxNeupogen 300 mcg single-dose vial
    55513-0546-xxNeupogen 480 mcg single-dose vial
    00069-0291-xxNivestym 300 mcg single-dose prefilled syringe
    00069-0294-xxNivestym 480 mcg single-dose vial
    00069-0292-xxNivestym 480 mcg single-dose prefilled syringe
    61314-0246-xxZarxio 300 mcg single-dose vial
    61314-0318-xxZarxio 300 mcg single-dose prefilled syringe
    61314-0266-xxZarxio 480 mcg single-dose vial
    61314-0326-xxZarxio 480 mcg single-dose prefilled syringe
    1–10 of 13
    1/2
    Covered ICD-10 CodesICD-10Covered
    C64.1Malignant neoplasm of right kidney, except renal pelvis.
    C64.2Malignant neoplasm of left kidney, except renal pelvis.
    C64.9Malignant neoplasm of unspecified kidney, except renal pelvis.
    C65.1Malignant neoplasm of right renal pelvis.
    C65.2Malignant neoplasm of left renal pelvis.
    C65.9Malignant neoplasm of unspecified renal pelvis.
    C83.30Diffuse large B-cell lymphoma, unspecified site.
    C83.31Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck.
    C83.32Diffuse large B-cell lymphoma, intrathoracic lymph nodes.
    C83.33Diffuse large B-cell lymphoma, intra-abdominal lymph nodes.
    1–10 of 90
    1/9
    Max units per day — dosing limits for SA‑G‑CSF
    Severe chronic neutropenia1560 billable units/mcg per day
    BMT/PBPC/H-ARS1200 billable units/mcg per day
    All other indications600 billable units/mcg per day

    Provider Actions, Documentation & Billing Guidance

    Prior Authorization

    Prior authorization validity

    Prior authorization is required. Initial prior authorization validity will be provided for 4 months (120 days) and may be renewed every 4 months (120 days).

    Billing Rule

    HCPCS codes to use for prior authorization

    Use the HCPCS codes listed in the policy when requesting authorization or submitting claims. Billing units are defined as 1 billable unit = 1 mcg. Relevant codes include J1442, Q5110, Q5101, J1447, Q5125, Q5148; use J3590 or C9399 for Filkri/hospital outpatient unclassified reporting as applicable.

    • J1442, Q5110, Q5101, J1447, Q5125, Q5148
    • J3590 — Unclassified biologics (Filkri only)

    Background

    Short-acting granulocyte colony-stimulating factors are indicated to reduce the duration and severity of neutropenia in multiple clinical settings. They are used for prophylaxis of chemotherapy-induced febrile neutropenia, treatment of chemotherapy-induced febrile neutropenia, mobilization for peripheral blood progenitor cell collection and bone marrow transplant, support in acute myeloid leukemia, management of severe chronic neutropenia, CAR-T–related neutropenia, H-ARS, and certain pediatric oncology indications. When used to treat febrile neutropenia, the policy lists member risk factors (for example: sepsis syndrome; age >65; ANC <100/mcL; expected neutropenia >10 days; pneumonia or invasive fungal infection; hospitalization at fever; prior febrile neutropenia) that support coverage decisions.

    Definitions and Product Presentations

    Febrile neutropenia — definition and thresholds
    Temperature thresholdSingle oral temperature ≥38.3 °C or ≥38.0 °C over 1 hour
    Neutropenia thresholdAbsolute neutrophil count <500 neutrophils/mcL, or <1,000 neutrophils/mcL with predicted decline to ≤500 over 48 hours
    Reference guidanceIncidence examples available in the NCCN Hematopoietic Growth Factors Clinical Practice Guideline
    Zarxio — listed presentations & NDCs
    Zarxio presentations300 mcg single-dose vial (NDC 61314-0246-xx) and 300 mcg prefilled syringe (NDC 61314-0318-xx); 480 mcg single‑dose vial (NDC 61314-0266-xx) and 480 mcg prefilled syringe (NDC 61314-0326-xx)
    Use for billing/identificationUse listed NDCs to support claims and dispensing accuracy

    Revision History & Appendices

    2026-07-01policy_reviewLatest

    Policy IC-0235 last reviewed and effective date recorded as 2026-07-01 (routine clinical review).

    2025-11-01reference_update

    Granix package insert (Reference 5) dated November 2023 cited in references and accessed for policy support in 2025.

    2025-08-01reference_update
    Policy Summary
    PayerViva Health
    PolicyShort-Acting Granulocyte Colony Stimulating Factors (SA-G-CSF)
    Policy CodePolicy IC-0235
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (initial validity 120 days) and document prior use or contraindication/intolerance/failure to Nivestym and Zarxio when requesting alternative short-acting G-CSF.
    SourceLink
    On This Page
    Coverage Criteria for Short-Acting G-CSFCoding and Billing CodesProvider Actions, Documentation & Billing GuidanceBackgroundDefinitions and Product PresentationsRevision History & Appendices
  1. C9399 — Unclassified drugs/biologicals (hospital outpatient, Filkri only)
  2. Billing unit: 1 billable unit = 1 mcg
  3. Note

    NDC listing only — no PA specified in this section

    These document excerpts present NDC numbers only and do not specify any prior authorization requirements in this section.

    Note

    NDC entries without PA rules

    The cited excerpts list product NDCs and presentations (strengths and container types) but do not state prior authorization requirements.

    Note

    NDC listing — no PA specified

    This portion of the policy provides NDC listings only and does not specify prior authorization requirements for the listed products.

    Documentation Required

    NDC listing for billing/identification (no PA stated)

    The policy supplies NDCs for covered short-acting G‑CSF products for billing/identification; prior authorization requirements (if any) are not specified in this portion.

    Note

    NDC reference (no PA rules in this excerpt)

    This excerpt provides NDC identifiers for products; no prior authorization rules are stated in this chunk.

    Note

    NDC listings only — no PA specified

    These chunks present NDC listings and do not state prior authorization requirements for the products shown.

    Note

    NDC listings without explicit PA language

    Only NDC listings and product identifiers appear in these excerpts; no prior authorization codes or explicit PA requirements are provided here.

    Prior Authorization

    Prior authorization may be required (NQTL considerations)

    Utilization management prior authorization was considered due to the drug indication and cost; prior authorization may be applied per the NQTL checklist.

    • NQTL factors considered include indication and cost and support consideration for PA (Appendix A).
    Step Therapy

    Required trial of preferred agents (Nivestym and Zarxio)

    Member must have a contraindication, intolerance, or documented failure to both Nivestym and Zarxio before another short-acting G‑CSF product will be considered.

    • Document prior use and reason for discontinuation (contraindication, intolerance, or treatment failure) for Nivestym and Zarxio.
    Documentation Required

    Required clinical documentation — prior use and reason

    Document prior use of Nivestym and Zarxio and record the clinical reason (contraindication, intolerance, or failure) before other short‑acting G‑CSF agents will be considered.

    • Indicate the specific covered indication and supporting clinical details (ANC values, risk factors, chemotherapy regimen risk level, prior responses).
    Billing Rule

    Required documentation for billing — product, dose, units/NDC

    Document the product name and dose (mcg) and align billing units with the HCPCS billing definition (1 billable unit = 1 mcg) or use the appropriate NDC on the claim.

    • Record product name and mcg dose on documentation and claim.
    • Match billed units to HCPCS (1 unit = 1 mcg) or include the correct NDC for pharmacy billing.
    Billing Rule

    NDCs for Zarxio, Releuko, Neupogen, Nivestym (use for billing)

    NDC listings for Zarxio, Releuko, Neupogen, and Nivestym are provided to support product identification and billing; refer to the listed NDCs when submitting claims or PA requests.

    • Use the listed NDC(s) for the exact product strength and presentation on claims or prior authorization forms.
    Documentation Required

    NDC presentation guidance for billing/identification

    The document provides NDC numbers paired with product presentations (strength and single‑dose vial or prefilled syringe); reference these when identifying products for dispensing or claims.

    • Refer to NDC plus presentation (e.g., 300 mcg vial, 480 mcg syringe) when documenting product dispensed.
    Billing Rule

    NDC codes for pharmacy billing (identification only)

    Use the listed NDC codes for pharmacy billing and product identification; this section does not change dosing rules but supports accurate claim submissions.

    Documentation Required

    Use listed NDCs on claims and PA requests

    When submitting claims or prior authorization requests for short‑acting G‑CSF products, include the listed NDC(s) to ensure accurate drug identification on the request or claim.

    Documentation Required

    NDC identifiers for PA and claims

    These sections list NDC identifiers for short‑acting G‑CSF products; use the provided NDCs to identify the drug on claims and prior authorization forms.

    Documentation Required

    Supporting references to support documentation

    References including package inserts and the NCCN Drugs & Biologics Compendium are provided and may be used to support clinical documentation submitted for prior authorization.

    • Package inserts for Neupogen, Nivestym, Zarxio, Releuko, Granix, Nypozi are cited.
    • NCCN Drugs & Biologics Compendium entries are listed as supporting references.
    Documentation Required

    Submit covered diagnosis code from Appendix 1

    Submit an appropriate covered ICD‑10 diagnosis code from Appendix 1 with the authorization or claim to support coverage (examples include D70.1 — agranulocytosis secondary to cancer chemotherapy; Z51.11 — encounter for antineoplastic chemotherapy).

    • Include one of the covered ICD‑10 codes from Appendix 1 on the PA form or claim.
    Denial Risk

    Denial risk: unacceptable toxicity on renewal

    Renewal may be denied if the member exhibits unacceptable toxicity from the drug; examples include splenic rupture, ARDS, serious allergic reactions/anaphylaxis, sickle cell crisis, glomerulonephritis, leukocytosis, capillary leak syndrome, potential tumor growth stimulation, aortitis, alveolar hemorrhage/hemoptysis, thrombocytopenia, cutaneous vasculitis, or treatment‑related MDS/AML.

    • If unacceptable toxicity is present, prior authorization renewal may be denied.
    Denial Risk

    Coding/claim risk — use listed HCPCS or appropriate unclassified codes

    Claims submitted without the listed HCPCS codes (or without using J3590/C9399 for Filkri in applicable outpatient settings) or without the appropriate NDCs may be denied or miscoded, placing claims at risk for denial or mispayment.

    • Use the specific HCPCS codes listed in the policy when billing.
    • For Filkri, use J3590 or hospital outpatient C9399 as indicated.
    Note

    Prior authorization considered per NQTL checklist

    Utilization management prior authorization was considered in design of this policy (see Appendix A); indication and drug cost were factors leading to consideration of PA.

    • Appendix A (NQTL checklist) documents that indication and cost supported consideration for prior authorization.
    Source noteNDC patterns shown repeatedly across document fragments
    Neupogen — listed presentations & NDCs
    Neupogen presentations300 mcg single-dose vial (NDC 55513-0530-xx) and 300 mcg prefilled syringe SingleJect (NDC 55513-0924-xx); 480 mcg single-dose vial (NDC 55513-0546-xx)
    Use for billing/identificationUse listed NDCs to support claims and dispensing accuracy
    Source noteNeupogen NDCs appear across multiple NDC listing sections
    Nivestym — listed presentations & NDCs
    Nivestym presentations300 mcg single‑dose prefilled syringe (NDC 00069-0291-xx); 480 mcg single‑dose vial (NDC 00069-0294-xx) and 480 mcg prefilled syringe (NDC 00069-0292-xx)
    Use for billing/identificationUse listed NDCs to support claims and dispensing accuracy
    Source noteNivestym NDCs listed in multiple fragments of the document
    Releuko — listed presentations & NDCs
    Releuko presentations300 mcg single‑dose vial (NDC 70121-1569-xx) and 300 mcg prefilled syringe (NDC 70121-1568-xx)
    Use for billing/identificationUse listed NDCs to support claims and dispensing accuracy
    Source noteReleuko 300 mcg entries present across NDC lists
    NDC entries for SA‑GCSF products — strengths & presentations
    Common strengths/presentations referencedExamples include 300 mcg single‑dose vial and 300 mcg prefilled syringe, and 480 mcg presentations where available
    NDC pattern usageDocument lists NDC patterns (xx suffix) identifying product, strength, and container type
    PurposeNDCs are provided to support dispensing and claim submission accuracy
    NDC list for SA G‑CSF — product, strength, container type
    NDC identificationDocument lists National Drug Codes that identify manufacturer product, strength (300 mcg, 480 mcg), and container type (single‑dose vial or prefilled syringe)
    Examples includedNeupogen (55513-0530-xx, 55513-0924-xx, 55513-0546-xx); Zarxio (61314-0246-xx, 61314-0318-xx, 61314-0266-xx, 61314-0326-xx); Nivestym (00069-0291-xx, 00069-0292-xx, 00069-0294-xx); Releuko (70121-1568-xx, 70121-1569-xx)
    Repeated listingsNDC entries are repeated across multiple sections/chunks for completeness of product presentation listings
    NCCN Compendium and package insert references
    NCCN Compendium entriesNCCN Drugs & Biologics Compendium references for filgrastim and Hematopoietic Growth Factors are cited as supporting references
    Package inserts citedNeupogen, Nivestym, Zarxio, Releuko, Granix, Nypozi package inserts are included in references
    Access informationNCCN Compendium and package inserts noted with access dates in 2025

    Zarxio package insert (Reference 3) dated August 2025 added to references and accessed October 2025.

    2025-07-01reference_update

    Nivestym package insert (Reference 2) dated July 2025 added to references and accessed October 2025.

    2025-06-01reference_update

    Neupogen package insert (Reference 1) dated June 2025 added to references and accessed October 2025.

    2025-06-01reference_update

    Nypozi package insert (Reference 6) dated June 2024 included in references and accessed October 2025.

    Note
    Note
    Note